Related Experiment Video
Updated: Jul 8, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple negative breast cancer: current understanding of biology and treatment options
Soonmo Peter Kang1, Maritza Martel, Lyndsay N Harris
1Section of Medical Oncology, Yale University School of Medicine/Yale Cancer Center, New Haven, Connecticut 06510, USA.
Purpose Of Review:
We have made remarkable advances in treatment of breast cancer with combination chemotherapies, hormonal therapies, and modern targeted therapies. Triple negative breast cancers carry a poor prognosis, however, and they are insensitive to most available hormonal or targeted therapeutic agents thus far developed. A better understanding of pathophysiology, natural history, and currently available treatment options is necessary to improve outcomes of patients with triple negative breast cancer.
Recent Findings:
Gene expression profiling has allowed us to classify breast cancers into five subtypes based upon distinctive gene expression signatures. This subtyping is prognostic, and the recent literatures suggest that these 'molecular portraits' may be used to predict treatment outcomes in the future.
Summary:
As we prepare for an era of targeted and individualized medicine, limited understanding of triple negative breast cancer biology presents a challenge in developing novel therapies. Identification of more molecular predictive signatures and their prospective validation will enable us to characterize triple negative breast cancers better and design optimal treatment modalities.
Insights
Triple negative breast cancer (TNBC) lacks effective treatments. Advances in gene expression profiling identify subtypes, offering hope for personalized therapies and improved outcomes for this aggressive breast cancer subtype.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Breast cancer treatment has advanced significantly with combination chemotherapy, hormonal therapy, and targeted agents.
- Triple negative breast cancer (TNBC) presents a poor prognosis due to its resistance to current hormonal and targeted therapies.
Purpose of the Study:
- To highlight the need for a deeper understanding of TNBC pathophysiology, natural history, and treatment options.
- To discuss the role of molecular subtyping in predicting treatment outcomes for breast cancer.
Main Methods:
- Review of recent literature on breast cancer subtyping using gene expression profiling.
- Analysis of the prognostic and predictive value of identified molecular subtypes.
Main Results:
- Gene expression profiling has classified breast cancers into five distinct molecular subtypes.
- These molecular subtypes are prognostic, and emerging evidence suggests they can predict treatment response.
Conclusions:
- Limited understanding of TNBC biology hinders the development of novel therapeutic strategies.
- Identifying and validating more molecular predictive signatures is crucial for better characterization and optimal treatment design for TNBC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer
